Samsung Bioepis launches Ustekinumab biosimilar in Japan with Nipro

Samsung Bioepis announced Wednesday the launch of its Ustekinumab biosimilar in Japan, marking the company’s first product debut in the country under a partnership with NIPRO Corp. The product, Ustekinumab BS 45 mg Syringe for S.C. Injection “NIPRO,” was listed under Japan’s National Health Insurance (NHI) drug price standard following an Official Gazette announcement on Tuesday, becoming effective the same day. The launch represents Samsung Bioepis’ entry into the Japanese biosimilars market through its collaboration with Nipro. “We are thrilled to announce the launch of our first biosimilar product in Japan in partnership with Nipro,” said Chung Jin-han, vice president and head of commercial strategy for international markets at Samsung Bioepis. “Together with our partner, we look forward to supporting patients living with autoimmune diseases and contributing to the sustainability of Japan’s health care system by providing quality-assured, safe and effective biosimilar options.” Ustekinumab is a human immunoglobulin G1 kappa monoclonal antibody designed to inhibit thWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times